Skip to Content
A Research Network of the Division of Cancer Prevention

CCOP - Community Clinical Oncology Program

  1. Home
  2. Contact the Program
  3. For Members

Treatment

The challenge during the creation of the CCOP program in the early 1980s was to design and implement a program to assure that cancer patients treated in their communities had access to clinical trial quality medical care. By introducing up-to-date cancer management into the community in the form of research clinical trials, community physicians would also be more ready and able to apply the proven treatment regimens to all their patients. Diffusion of state-of-the art cancer treatment to the practices where people were being treated would be enhanced.

The Request for Application released July 16, 1982 had the goal of selecting organizations of hospitals and medical practices that would take part in treatment trials, and build a network for cancer prevention and control trials.

Today, the CCOP network takes part in NCI cancer treatment trials reviewed and approved by the NCI Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP). Cancer prevention and control protocols are reviewed and approved by the NCI Division of Cancer Prevention (DCP) Community Oncology and Prevention Trials Research Group staff. There is great cooperation and collaboration between these programs and their staffs, and the CCOP network sites benefit from the seamless integration of systems.

 

Selected Publications

  • Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008 Oct 23;359(17):1757-65.
    [ PubMed Abstract ]
  • Laliberte L, Fennell ML, Papandonatos G. The relationship of membership in research networks to Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab inadvanced colorectal cancer. N Engl J Med. 2008 Oct 23;359(17):1757-65.
    [ PubMed Abstract ]
  • McKinney MM, Barnsley JM, Kaluzny AD. Organizing for cancer control. The diffusion of a dynamic innovation in a community cancer network. Int J Technol Assess Health Care. 1992 Spring;8(2):268-88.
  • [ PubMed Abstract ]
  • Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1673-84.
    [ PubMed Abstract ]
  • Warnecke RB, Johnson TP, Kaluzny AD, Ford LG. The Community Clinical Oncology Program: Its effect on clinical practice. Jt Comm J Qual Improv. 1995 July;21(7):336-9.
  • [ PubMed Abstract ]
  • Zujewski JA, Kamin L. Trial assessing individualized options for treatment for breast cancer: the TAILORx trial. Future Oncol. 2008 Oct;4(5): 603-10.
    [ PubMed Abstract ]

Top